Literature DB >> 19539080

Eligibility of individuals with subclinical coronary artery calcium and intermediate coronary heart disease risk for reclassification (from the Framingham Heart Study).

Sarah Rosner Preis1, Shih-Jen Hwang, Caroline S Fox, Joseph M Massaro, Daniel Levy, Udo Hoffmann, Christopher J O'Donnell.   

Abstract

Coronary artery calcium (CAC) predicts risk for coronary heart disease (CHD) events and perhaps CAC testing may further stratify risk in individuals at intermediate CHD risk. We sought to determine the percentage of participants at intermediate CHD risk who could potentially be reclassified as having a high CHD risk based on the presence of a high CAC score and the prevalence, treatment, and control of CHD risk factors in this group. Framingham Heart Study Offspring and Third Generation cohort participants underwent multidetector computed tomography (n = 3,529, mean age 51 years, 48% women). High CAC was defined as >or=90th age- and gender-specific percentiles based on a healthy reference group or by an absolute modified Agatston score of 100 HU. Prevalence of CHD risk factors (hypertension, hypercholesterolemia, high low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol, smoking, and obesity), their treatment, and control was compared between nondiabetic participants with and without high CAC. Of the 595 participants at intermediate CHD risk, 22% had CAC >or=90th percentile and 39% had CAC >or=100 and could be eligible for reclassification as having a high CHD risk based on the presence of a high CAC score. There were no statistically significant differences in prevalence, treatment, and control of risk factors between those with and without high CAC. In conclusion, prevalence of CHD risk factors did not differ between intermediate-risk participants with and without high CAC. Approximately 25% of intermediate-risk individuals have high CAC scores and may be eligible for reclassification into a higher-risk category.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539080      PMCID: PMC3042246          DOI: 10.1016/j.amjcard.2009.02.020

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  27 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Use of electron beam tomography data to develop models for prediction of hard coronary events.

Authors:  P Raggi; B Cooil; T Q Callister
Journal:  Am Heart J       Date:  2001-03       Impact factor: 4.749

3.  Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.

Authors:  G R Dagenais; S Yusuf; M G Bourassa; Q Yi; J Bosch; E M Lonn; S Kouz; J Grover
Journal:  Circulation       Date:  2001-07-31       Impact factor: 29.690

4.  The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination.

Authors:  Greta Lee Splansky; Diane Corey; Qiong Yang; Larry D Atwood; L Adrienne Cupples; Emelia J Benjamin; Ralph B D'Agostino; Caroline S Fox; Martin G Larson; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Philip A Wolf; Daniel Levy
Journal:  Am J Epidemiol       Date:  2007-03-19       Impact factor: 4.897

5.  Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults.

Authors:  J A Hoff; E V Chomka; A J Krainik; M Daviglus; S Rich; G T Kondos
Journal:  Am J Cardiol       Date:  2001-06-15       Impact factor: 2.778

6.  Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events.

Authors:  N D Wong; J C Hsu; R C Detrano; G Diamond; H Eisenberg; J M Gardin
Journal:  Am J Cardiol       Date:  2000-09-01       Impact factor: 2.778

7.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

8.  Coronary artery calcium: accuracy and reproducibility of measurements with multi-detector row CT--assessment of effects of different thresholds and quantification methods.

Authors:  Cheng Hong; Kyongtae T Bae; Thomas K Pilgram
Journal:  Radiology       Date:  2003-05-01       Impact factor: 11.105

9.  Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults.

Authors:  George T Kondos; Julie Anne Hoff; Alexander Sevrukov; Martha L Daviglus; Daniel B Garside; Stephen S Devries; Eva V Chomka; Kiang Liu
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

10.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

View more
  8 in total

1.  Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.

Authors:  Amit Pursnani; Joseph M Massaro; Ralph B D'Agostino; Christopher J O'Donnell; Udo Hoffmann
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

2.  Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study.

Authors:  Amit Pursnani; Joseph M Massaro; Ralph B D'Agostino; Christopher J O'Donnell; Udo Hoffmann
Journal:  J Clin Oncol       Date:  2017-07-12       Impact factor: 44.544

3.  Relation of Risk Factors and Abdominal Aortic Calcium to Progression of Coronary Artery Calcium (from the Framingham Heart Study).

Authors:  Oyere K Onuma; Karol Pencina; Saadia Qazi; Joseph M Massaro; Ralph B D'Agostino; Michael L Chuang; Caroline S Fox; Udo Hoffmann; Christopher J O'Donnell
Journal:  Am J Cardiol       Date:  2017-03-01       Impact factor: 2.778

4.  Leisure sport activity as a trigger for acute coronary events in men without known coronary artery disease : a single-center case study.

Authors:  A Cuneo; R Oeckinghaus; U Tebbe
Journal:  Herz       Date:  2011-06-16       Impact factor: 1.443

5.  Distribution, determinants, and normal reference values of thoracic and abdominal aortic diameters by computed tomography (from the Framingham Heart Study).

Authors:  Ian S Rogers; Joseph M Massaro; Quynh A Truong; Amir A Mahabadi; Matthias F Kriegel; Caroline S Fox; George Thanassoulis; Eric M Isselbacher; Udo Hoffmann; Christopher J O'Donnell
Journal:  Am J Cardiol       Date:  2013-03-13       Impact factor: 2.778

Review 6.  70-year legacy of the Framingham Heart Study.

Authors:  Charlotte Andersson; Andrew D Johnson; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan
Journal:  Nat Rev Cardiol       Date:  2019-11       Impact factor: 32.419

7.  Cardiovascular Event Prediction and Risk Reclassification by Coronary, Aortic, and Valvular Calcification in the Framingham Heart Study.

Authors:  Udo Hoffmann; Joseph M Massaro; Ralph B D'Agostino; Sekar Kathiresan; Caroline S Fox; Christopher J O'Donnell
Journal:  J Am Heart Assoc       Date:  2016-02-22       Impact factor: 5.501

8.  Quantifying the impact of using Coronary Artery Calcium Score for risk categorization instead of Framingham Score or European Heart SCORE in lipid lowering algorithms in a Middle Eastern population.

Authors:  Hussain A Isma'eel; Mohamad M Almedawar; Bernard Harbieh; Wissam Alajaji; Laila Al-Shaar; Mukbil Hourani; Fadi El-Merhi; Samir Alam; Antoine Abchee
Journal:  J Saudi Heart Assoc       Date:  2015-05-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.